- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00809198
Kynex Versus Refresh Plus Study in Subject With Dry Eye
February 1, 2012 updated by: Alcon Research
The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study
The effect of Kynex versus Refresh Plus in subjects with mild to moderate dry eye.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 20 years of age or older, of any race and either sex.
- Able to understand and sign an informed consent that has been approved by an Institutional Review Board.
- Criteria for the diagnosis must include the following two characteristics at Visit 1 (Day 1):
- Subjects' assessment of dry eye status (answer of at least "Some of the time" to the question, "How often have your eyes felt dry enough to want to use eye drops?"
- Sodium fluorescein (NaFl) corneal staining score sum of ≥3 in either eye (NEI scoring system).
- Able and willing to follow study instructions.
Exclusion Criteria:
- Subjects who meet any of the following criteria will be excluded from this study:
- History or evidence of ocular or intraocular surgery in either eye within the past three months.
- History of intolerance or hypersensitivity to any component of the study medications.
- History or evidence of epithelial herpes simplex keratitis (dendrictic keratitis); vaccine, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular rosacea; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye.
- Use of topical ocular medications during the study period.
- Subjects using systemic medications that may contribute to dry eye (e.g. cold and allergy medications, tricyclic antidepressants, hormone replacement therapies) may not be enrolled in the study unless they have been on a stable dosing regimen for a minimum of 30 days prior to Visit 1. In addition, the dosing regimen must remain stable throughout the study.
- Presence of ocular conditions such as active acute blepharitis, conjunctival infections, iritis, or any other ocular condition that may preclude the safe administration of the test article.
- Subjects unwilling to discontinue contact lens wear during the study period. Contact lens wear must have been discontinued at least one week prior to Visit 1.
- Current punctal occlusion of any type (e.g. collagen plugs, silicone plugs).
- Enrollment of the investigator or his or her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
- Participation in any investigational drug or device study within 30 days of entering this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sodium Hyaluronate
Sodium Hyaluronate (Kynex)
|
Other Names:
|
ACTIVE_COMPARATOR: Carboxymethylcellulose sodium
Carboxymethylcellulose sodium (Refresh Plus)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cornea Staining Score
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dry Eye and symptoms
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (ACTUAL)
May 1, 2009
Study Completion (ACTUAL)
May 1, 2009
Study Registration Dates
First Submitted
December 16, 2008
First Submitted That Met QC Criteria
December 16, 2008
First Posted (ESTIMATE)
December 17, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
February 3, 2012
Last Update Submitted That Met QC Criteria
February 1, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Immunologic Factors
- Gastrointestinal Agents
- Protective Agents
- Adjuvants, Immunologic
- Viscosupplements
- Laxatives
- Hyaluronic Acid
- Carboxymethylcellulose Sodium
Other Study ID Numbers
- RM-08-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Sodium Hyaluronate
-
Democritus University of ThraceGeorge Papanicolaou Hospital; Naval Hospital, Athens; Athinaiki General ClinicCompleted
-
DiscGenics, Inc.CTI Clinical Trial and Consulting ServicesCompletedDegenerative Disc DiseaseUnited States
-
Peking University People's HospitalUnknown
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityUnknownDry Eye | Cataract SenileChina
-
Ferring PharmaceuticalsCompletedInvestigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the KneeOsteoarthritis of the KneeUnited States
-
Laboratorios Sophia S.A de C.V.Completed
-
Laboratorios Sophia S.A de C.V.Completed
-
Hasanuddin UniversityCompleted
-
Laboratorios Sophia S.A de C.V.Active, not recruitingDry Eye SyndromesMexico